La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Kiora Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Kiora Pharmaceuticals ha un patrimonio netto totale di $33.1M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $40.8M e $7.7M. L'EBIT di Kiora Pharmaceuticals è $6.3M rendendo il suo rapporto di copertura degli interessi -9.7. Ha liquidità e investimenti a breve termine pari a $27.8M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	-9.7x
Contanti	US$27.82m
Patrimonio netto	US$33.10m
Totale passività	US$7.71m
Totale attività	US$40.81m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

May 21

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Oct 13

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $31.8M ) di KPRX superano le sue passività a breve termine ( $1.7M ).

Passività a lungo termine: Le attività a breve termine di KPRX ( $31.8M ) superano le sue passività a lungo termine ( $6.1M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: KPRX è esente da debiti.

Riduzione del debito: KPRX non aveva debiti 5 anni fa.

Copertura del debito: KPRX non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.

Copertura degli interessi: KPRX non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.

Kiora Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Kiora Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Kiora Pharmaceuticals, Inc. announced delayed 10-Q filing

Kiora Pharmaceuticals, Inc. announced delayed annual 10-K filing

Recent updates

Consensus EPS estimates increase by 64%, revenue downgraded

New major risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Kiora Pharmaceuticals, Inc. Announces Board and Committee Changes

Investor sentiment improves as stock rises 21%

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024

New major risk - Revenue and earnings growth

Price target decreased by 69% to US$3.83

New major risk - Share price stability

Price target increased by 42% to US$17.50

Kiora Pharmaceuticals, Inc. Announces Board Changes

New major risk - Revenue and earnings growth

Price target decreased by 56% to US$20.00

Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director

Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target increased by 39% to US$65.50

Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301

Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases

High number of new directors

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Kiora Pharma announces 1-for-40 reverse stock split

Kiora Pharmaceuticals, Inc. Appoints Melissa Tosca as Executive Vice President of Finance

Kiora Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

High number of new directors

Kiora Pharmaceuticals, Inc., Annual General Meeting, Sep 23, 2022

Kiora Pharmaceuticals reports 1H results

Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing

Kiora Pharmaceuticals prices $5.2M underwritten public offering

Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201

Kiora Pharmaceuticals, Inc. Announces Brian M. Strem Will Assume Role of its Principal Financial and Accounting Officer

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Kiora Pharmaceuticals, Inc. announced delayed 10-Q filing

Kiora Pharmaceuticals, Inc. Appoints Susan L. Drexler as Interim Chief Financial Officer

Kiora Pharmaceuticals, Inc. announced delayed annual 10-K filing

Kiora Pharmaceuticals, Inc. Appoints Michael Meluzio as Principal Financial Officer and Principal Accounting Officer

Kiora Pharmaceuticals, Inc. Announces Resignation of Sarah Romano as Chief Financial Officer, Effective February 25, 2022

Kiora Pharmaceuticals, Inc. Announces Executive Changes

No longer forecast to breakeven

EyeGate Pharmaceuticals, Inc. Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

Price target decreased to US$11.83

EyeGate Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $10.750013 million.

Director Steven Boyd has left the company

Director I. Maher has left the company

EyeGate Pharmaceuticals, Inc. Announces First Patient Dosed for PP-001 in A Phase 2 Proof-Of-Concept Ocular Surface Inflammation Study

No longer forecast to breakeven

Price target decreased to US$13.08

Full year 2020 earnings released: US$1.77 loss per share (vs US$2.23 loss in FY 2019)

New 90-day high: US$7.30

EyeGate Pharmaceuticals, Inc. Announces Board Appointments

New 90-day high: US$6.63

EyeGate Pharmaceuticals announces $8M private placement

Price target raised to US$12.83

EyeGate Pharmaceuticals, Inc. (NasdaqCM:EYEG) entered into a share purchase agreement to acquire Panoptes Pharma GES.M.B.H for $15 million.

New 90-day high: US$5.21

EyeGate surge in premarket as it acquires Panoptes Pharma for $4M

Earnings beat expectations

New 90-day low: US$3.57

Price target lowered to US$11.17

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane